This topic contains a solution. Click here to go to the answer

Author Question: The textbook rejects the cost-plus-markup theory of price setting because A) business firms do ... (Read 111 times)

2125004343

  • Hero Member
  • *****
  • Posts: 566
The textbook rejects the cost-plus-markup theory of price setting because
 
  A) business firms do not describe their price-setting procedures as cost-plus procedures.
  B) competitors and monopolists set prices in different ways.
  C) it cannot explain the prices we actually observe.
  D) it ignores the role of government in regulating prices.
  E) no single theory can explain all price-setting.

Question 2

A merger between a firm extracting petroleum and a firm refining petroleum is a
 
  A) conglomerate merger.
  B) diagonal merger.
  C) horizontal merger.
  D) vertical merger.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

amandanbreshears

  • Sr. Member
  • ****
  • Posts: 320
Answer to Question 1

C

Answer to Question 2

D




2125004343

  • Member
  • Posts: 566
Reply 2 on: Jun 29, 2018
Wow, this really help


xiaomengxian

  • Member
  • Posts: 311
Reply 3 on: Yesterday
:D TYSM

 

Did you know?

In the United States, congenital cytomegalovirus causes one child to become disabled almost every hour. CMV is the leading preventable viral cause of development disability in newborns. These disabilities include hearing or vision loss, and cerebral palsy.

Did you know?

Human neurons are so small that they require a microscope in order to be seen. However, some neurons can be up to 3 feet long, such as those that extend from the spinal cord to the toes.

Did you know?

There are approximately 3 million unintended pregnancies in the United States each year.

Did you know?

The effects of organophosphate poisoning are referred to by using the abbreviations “SLUD” or “SLUDGE,” It stands for: salivation, lacrimation, urination, defecation, GI upset, and emesis.

Did you know?

For high blood pressure (hypertension), a new class of drug, called a vasopeptidase blocker (inhibitor), has been developed. It decreases blood pressure by simultaneously dilating the peripheral arteries and increasing the body's loss of salt.

For a complete list of videos, visit our video library